Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Avalo Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 29 | 33 | +4 |
| Shares | 6.66M | 7.53M | +873.6K (+13.1%) |
| Value | $63.2M | $56.0M | −$7.25M (−11.5%) |
New holders (9)
Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Royal Bank of Canada | 117,356 | $872.0K | 0.00% |
| Velan Capital Investment Management LP | 109,972 | $817.1K | 0.71% |
| Allostery Investments LP | 73,314 | $544.7K | 1.07% |
| Bank of Montreal | 60,000 | $445.8K | 0.00% |
| HRT Financial LP | 40,000 | $297.0K | 0.00% |
| Northern Trust Corp | 22,673 | $168.5K | 0.00% |
| Walleye Capital LLC | 19,477 | $144.7K | 0.00% |
| Marshall Wace, LLP | 15,323 | $113.8K | 0.00% |
| SBI Securities Co., Ltd. | 22 | $163 | 0.00% |
Sold out (5)
Institutions that held Avalo Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Logos Global Management LP | 539,079 | $5.12M |
| Wells Fargo & Company | 1 | $10 |
| Jaffetilchin Investment Partners, LLC | 1 | $10 |
| FMR LLC | 1 | $9 |
| Avion Wealth | 5 | $0 |